Nevisense system tests lesions before biopsy for melanoma

SciBase won FDA approval to introduce its Nevisense system to help dermatologists assess suspect cutaneous lesions that may be melanoma tumours. Unlike many technologies that have been attempted to characterise cancerous lesions, this one uses electrical impedance rather than optical methods. The system delivers electric current at different frequencies through the lesion using a pen-like device.

Melanoma tumour cells transmit electricity somewhat differently from normal healthy cells, and the effect of this can be detected using electrical impedance spectroscopy. Reference measurements taken in the past allow the system to compare with those and point to suspect melanoma during the exam.

The physician simply moistens the skin over the lesion, wipes off, and measures by placing the pen tip against the lesion. The table-top touchscreen display then provides a spectrogram of the readings and how out of normal range they are. Having this information dermatologists may then be able to form a better idea of whether to move toward biopsy of the suspect lesion.

Keep Up to Date with the Most Important News

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Terms of Use
Previous Post

Elon Musk drives early release of Tesla Model 3 electric car

Next Post

Early-stage breast cancer patients can receive expedited treatment